SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-021934
Filing Date
2020-05-06
Accepted
2020-05-06 16:11:22
Documents
14
Period of Report
2020-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-8k_20200506.htm   iXBRL 8-K 36845
2 EX-99.1 rare-ex991_6.htm EX-99.1 141054
3 GRAPHIC gtwixdmaweak000001.jpg GRAPHIC 348834
  Complete submission text file 0001564590-20-021934.txt   797522

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rare-20200506.xsd EX-101.SCH 5784
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rare-20200506_lab.xml EX-101.LAB 18721
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rare-20200506_pre.xml EX-101.PRE 11179
13 EXTRACTED XBRL INSTANCE DOCUMENT rare-8k_20200506_htm.xml XML 3414
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 20852719
SIC: 2834 Pharmaceutical Preparations